- LIVING WITH HIV/AIDS
- SOCIAL ISSUES
- ABOUT US
- NEWS & INFORMATION
CAS is continuing to monitor developments in the field of new prevention technologies through participation in meetings and teleconferences, and updates from networks and publications.
In addition, London's Medical Research Council is also currently conducting a study on PRO 2000, which is three times the size of the first study. This study, MDP 301, involves 9,500 women. At the same time, the US National Institute of Allergy and Infectious Diseases (NIAID), the funder of the HPTN 035 trial, is in discussions with Indevus Pharmaceuticals to determine the way forward. NIAID will decide whether to fund additional studies of PRO 2000 after data from MDP 301 are available.
New Prevention Technologies Updates. © Canadian AIDS Society. Published 07/24/2009. Updated 02/17/2011. Web. Retrieved 05/21/2013 from http://www.cdnaids.ca/newpreventiontechnologiesupdates